Cargando…

VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients

OBJECTIVE: At present, maintenance therapy with the antiangiogenic agent bevacizumab or with PARP-inhibitors represent two options for BRCA-wildtype ovarian cancer patients, after platinum-based first line chemotherapy. The identification of molecular markers to predict patient response to different...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Yi, Oliveira-Ferrer, Leticia, Vettorazzi, Eike, Legler, Karen, Milde-Langosch, Karin, Woelber, Linn, Jaeger, Anna, Prieske, Katharina, Mueller, Volkmar, Schmalfeldt, Barbara, Kuerti, Sascha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9187059/ https://www.ncbi.nlm.nih.gov/pubmed/35687576 http://dx.doi.org/10.1371/journal.pone.0269680

Ejemplares similares

VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
por: Kuerti, Sascha, et al.
Publicado: (2017)

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer
por: Trillsch, Fabian, et al.
Publicado: (2016)

Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
por: Woelber, Linn, et al.
Publicado: (2021)

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
por: Prieske, Katharina, et al.
Publicado: (2017)

Pelvic lymphadenectomy in vulvar cancer and its impact on prognosis and outcome
por: Jaeger, A., et al.
Publicado: (2021)

TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
por: Mahner, Sven, et al.
Publicado: (2010)

Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer
por: Volk, Annabelle, et al.
Publicado: (2023)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2018)

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Elazezy, Maha, et al.
Publicado: (2021)

Comparison of PapilloCheck and Linear Array to Detect and Differentiate Human Papillomaviruses in Cervical and Tonsillar Smears from Females with Cervical Intraepithelial Lesions
por: Grimm, Donata, et al.
Publicado: (2018)

Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation
por: Hamester, Fabienne, et al.
Publicado: (2019)

Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer
por: Legler, Karen, et al.
Publicado: (2018)

Transcriptome Analysis in Vulvar Squamous Cell Cancer
por: Prieske, Katharina, et al.
Publicado: (2021)

Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2020)

The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer
por: Reuter, Susanne, et al.
Publicado: (2021)

The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients
por: Reimer, Francesca, et al.
Publicado: (2023)

Impact of Introducing a PACU24 Concept on the Perioperative Outcome of Patients with Advanced Ovarian Cancer Treated with Cytoreductive Surgery
por: Reuter, Susanne, et al.
Publicado: (2023)

Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer
por: Woelber, Linn, et al.
Publicado: (2011)

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients
por: Ihnen, Maike, et al.
Publicado: (2012)

Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany
por: Grimm, Donata, et al.
Publicado: (2020)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients
por: Leffers, Markus, et al.
Publicado: (2022)

Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients
por: Eichelser, Corinna, et al.
Publicado: (2014)

Molecular characteristics and tumorigenicity of ascites‐derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer
por: Ding, Yi, et al.
Publicado: (2021)

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
por: Meng, Xiaodan, et al.
Publicado: (2015)

Insights into the Steps of Breast Cancer–Brain Metastases Development: Tumor Cell Interactions with the Blood–Brain Barrier
por: Hamester, Fabienne, et al.
Publicado: (2022)

Key Role of Hyaluronan Metabolism for the Development of Brain Metastases in Triple-Negative Breast Cancer
por: Hamester, Fabienne, et al.
Publicado: (2022)

Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab
por: Krizova, Deli, et al.
Publicado: (2014)

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
por: Witzel, Isabell, et al.
Publicado: (2014)

Evaluation of cytotoxicity of bevacizumab on VEGF-enriched corneal endothelial cells
por: Rusovici, Raluca, et al.
Publicado: (2011)

Does anti-VEGF bevacizumab improve survival in experimental sepsis?
por: Besnier, Emmanuel, et al.
Publicado: (2017)

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
por: Papadopoulos, Nicholas, et al.
Publicado: (2012)

The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance
por: Alidzanovic, Lejla, et al.
Publicado: (2016)

Ovarian Cancer-Cell Pericellular Hyaluronan Deposition Negatively Impacts Prognosis of Ovarian Cancer Patients
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2022)

Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
por: Schargus, Marc, et al.
Publicado: (2021)

C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma
por: Mahner, S, et al.
Publicado: (2008)

Bevacizumab therapy normalizes the pathological intraocular environment beyond neutralizing VEGF
por: Sharma, Rajesh K., et al.
Publicado: (2010)

Morphological Changes of Cortical and Hippocampal Neurons after Treatment with VEGF and Bevacizumab
por: Latzer, Pauline, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8m7jqfl2cvh4jllm973412d94j